| Dr Christopher Doe, MD | |
|
1024 S Lemay Ave, Fort Collins, CO 80524-3929 | |
| (970) 495-7000 | |
| (970) 484-4759 |
| Full Name | Dr Christopher Doe |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 10 Years |
| Location | 1024 S Lemay Ave, Fort Collins, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194144113 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical Center Of The Rockies | Loveland, CO | Hospital |
| Poudre Valley Hospital | Fort collins, CO | Hospital |
| Uchealth Greeley Hospital | Greeley, CO | Hospital |
| Longs Peak Hospital | Longmont, CO | Hospital |
| Ivinson Memorial Hospital | Laramie, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Uchealth Imaging Services Llc | 5799021291 | 141 |
| Yampa Valley Medical Center | 5890685689 | 122 |
| Fort Collins Radiologic Associates Pc | 7315844396 | 55 |
News Archive
The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.
Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) announce the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow's members in the north of the UK and the wider UK sector.
New research published in the April issue of the Journal of the American College of Surgeons indicates that large numbers of physician assistants and nurse practitioners – collectively known as physician extenders (PEs) – have been hired by general surgery residency programs in the last five years to enable the resident education experience, and these professionals continue to be in demand.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 5 days ago
| Entity Name | Fort Collins Radiologic Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003849498 PECOS PAC ID: 7315844396 Enrollment ID: O20031217000768 |
News Archive
The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.
Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) announce the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow's members in the north of the UK and the wider UK sector.
New research published in the April issue of the Journal of the American College of Surgeons indicates that large numbers of physician assistants and nurse practitioners – collectively known as physician extenders (PEs) – have been hired by general surgery residency programs in the last five years to enable the resident education experience, and these professionals continue to be in demand.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 5 days ago
| Entity Name | Yampa Valley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790787307 PECOS PAC ID: 5890685689 Enrollment ID: O20040316001301 |
News Archive
The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.
Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) announce the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow's members in the north of the UK and the wider UK sector.
New research published in the April issue of the Journal of the American College of Surgeons indicates that large numbers of physician assistants and nurse practitioners – collectively known as physician extenders (PEs) – have been hired by general surgery residency programs in the last five years to enable the resident education experience, and these professionals continue to be in demand.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 5 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100602000122 |
News Archive
The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.
Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) announce the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow's members in the north of the UK and the wider UK sector.
New research published in the April issue of the Journal of the American College of Surgeons indicates that large numbers of physician assistants and nurse practitioners – collectively known as physician extenders (PEs) – have been hired by general surgery residency programs in the last five years to enable the resident education experience, and these professionals continue to be in demand.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 5 days ago
| Entity Name | Uchealth Imaging Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396210902 PECOS PAC ID: 5799021291 Enrollment ID: O20190103002022 |
News Archive
The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.
Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) announce the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow's members in the north of the UK and the wider UK sector.
New research published in the April issue of the Journal of the American College of Surgeons indicates that large numbers of physician assistants and nurse practitioners – collectively known as physician extenders (PEs) – have been hired by general surgery residency programs in the last five years to enable the resident education experience, and these professionals continue to be in demand.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Doe, MD 2008 Caribou Dr, Fort Collins, CO 80525-4325 Ph: (970) 484-4757 | Dr Christopher Doe, MD 1024 S Lemay Ave, Fort Collins, CO 80524-3929 Ph: (970) 495-7000 |
News Archive
The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.
Bionow, the BioIndustry Association (BIA), BioPartner and One Nucleus (ON) announce the formation of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare members across the UK and internationally. The aim of the partnership is to work together on a range of matters that directly benefit members including Bionow's members in the north of the UK and the wider UK sector.
New research published in the April issue of the Journal of the American College of Surgeons indicates that large numbers of physician assistants and nurse practitioners – collectively known as physician extenders (PEs) – have been hired by general surgery residency programs in the last five years to enable the resident education experience, and these professionals continue to be in demand.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.
› Verified 5 days ago
Dr. Tracy Haefele Florant, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 430 Spinnaker Ln, Fort Collins, CO 80525 Phone: 970-988-8637 | |
Karl E. Magsamen, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 Fax: 970-495-7639 | |
Dr. Karen B Alderfer, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Nathan Miller, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Kevin Limbaugh, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-8600 Fax: 970-495-7619 | |
Dr. Guy Thomas Alexander, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Audrey Marie Magnowski, MD Radiology Medicare: Medicare Enrolled Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 |